scispace - formally typeset
B

Bernhard Angermayr

Researcher at Medical University of Vienna

Publications -  31
Citations -  1545

Bernhard Angermayr is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Portal hypertension & Transjugular intrahepatic portosystemic shunt. The author has an hindex of 16, co-authored 31 publications receiving 1425 citations. Previous affiliations of Bernhard Angermayr include University of Vienna & University of Barcelona.

Papers
More filters
Journal ArticleDOI

Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt

TL;DR: Although MELD was the primary predictor of overall survival in multivariate analysis, c statistics showed that both scores can be used for patients undergoing TIPS with equal accuracy, and there seems little reason to replace the well established Child-Pugh score.
Journal ArticleDOI

Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats.

TL;DR: It is demonstrated that the development of hyperdynamic splanchnic circulation and the formation of portal-systemic collateral vessels in portal hypertensive rats are angiogenesis-dependent processes that can be markedly inhibited by blockade of the VEGF signaling pathway.
Journal ArticleDOI

Hypoxic hepatitis: underlying conditions and risk factors for mortality in critically ill patients

TL;DR: Hypoxic hepatitis is the consequence of multiorgan injury and outcome is influenced by the severity of liver impairment and the etiology and severity of the basic disease.
Journal ArticleDOI

Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents.

TL;DR: Patients undergoing ePTFE‐endoprosthesis implantation had higher survival rates within 2 years after TIPS‐implantation, which may be the result of improved patency rates after correct placement (up to the inferior caval vein [ICV]) of the eP TFE stentgraft.
Journal ArticleDOI

Impact of hypoxic hepatitis on mortality in the intensive care unit

TL;DR: The presence of HH is a strong risk factor for mortality in the ICU in patients requiring vasopressor therapy, and it is demonstrated that HH occurs frequently in the medical ICU.